{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-032627","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.503335+00:00","generated_at":"2026-05-18T23:33:14.518133+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"X4 Pharmaceuticals secures $40M equity line with Lincoln Park Capital","bullets":["Company may sell up to $40M of common stock to Lincoln Park over 24 months.","Purchase price set at 97% of the lower of lowest or 3-day-average closing price.","Regular purchases capped at 30k–60k shares per day based on stock price thresholds.","Issued 137,099 commitment shares to Lincoln Park as a fee for entering the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-032627","json":"https://secwatch.observer/filing/0001628280-25-032627.json","markdown":"https://secwatch.observer/filing/0001628280-25-032627.md","text":"https://secwatch.observer/filing/0001628280-25-032627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025032627/0001628280-25-032627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:33:14.518133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}